Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of palbociclib plus standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone in hormone receptor-positive, HER2-negative early breast cancer
MOH_2017-02-13_000112Phase 3Active, not recruiting
- Sponsor
- Austrian Breast and Colorectal Cancer Study Group
- Start
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of palbociclib in breast cancer (2 arms), sponsored by Austrian Breast and Colorectal Cancer Study Group. Primary endpoint: Invasive disease-free survival. Started Oct 2016; status: active, not recruiting.
02
Drugs
palbociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on MOH_2017-02-13_000112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-02-13_000112.